4D Path Inc. news
4D Path applies universal physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints. Its system runs on modern cloud components that enable dynamic scaling and batch processing, allowing 4D to optimize run times and deliver rapid results. Utilizing Microsoft Azure`s cloud technology, 4D Path has built stable and secure environments to host both research and regulated workflows fo
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development.
4D Path’s patented precision oncology platform unveils previously hidden data to inst
4D Path recently had the honor of including two publications in the virtual curriculum at the 2022 ASCO Annual Meeting. The publications addressed that the majority of druggable targets that drive oncogenic vulnerability are not expressed in a uniform or homogeneous manner throughout tumor tissue. Thus, intratumoral heterogeneity, as observed among the cells of an individual tumor, poses a major challenge in targeted therapy selec
PathPresenter, a pioneer in the development of digital pathology software, and 4D Path Inc., developer of a pan-cancer diagnostic and precision oncology platform enabling AI-based biomarker typing and prognostication from H&E images, are announcing today a global partnership to distribute 4D Q-plasia OncoReader Breast
Transitioning from his role as a 4D Path advisory board member, world-renowned cancer oncologist, health consultant, and entrepreneur Dr. Teich will now serve as 4D Path’s Chief Global Strategist. Dr. Teich’s expertise in facilitating clinical research and supporting innovative, evidence-based health technologies will support 4D Path’s efforts to bring more readily accessible and affordable care to different countries and their diverse systems, realities, and providers. Prio
4D Path, creator of a patented computer-aided pan-cancer diagnostic and precision oncology platform, is pleased to announce that Dr. Craig A. Bunnell, MD, MPH, MBA, has joined the company’s distinguished advisory board. A widely recognized authority in the field of medical oncology, Dr. Bunnell brings a wealth of experience in the treatment and management of breast cancer through clinical research, clinical trials, and correlative studies to 4
4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Dr. Nelson Teich, MD, MBA, MSc, has joined the company’s prestigious advisory board. A world-renowned oncologist, health consultant and entrepreneur in the field of clinical oncology, Teich will act as a global ambassador for 4D Path’s cloud-based, quantitative approach, which delivers diagnostic outcomes and enabl
4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, has extended its existing partnership with the University of Leeds in the UK through 2027, the two organizati
4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter, MD, MPH, MBA, has joined the company’s distinguished advisory board. Dr. Carter has a longstanding passion for applying emerging technologies across precision medicine, digital heath and AI applications to improve patient access to healthcare.
Dr. Carter is managing director of JLC Precision Health Strategies, LLC., which partners wi
4D Path, a company conceived by an experienced team of scientists, clinicians and management from leading research institutions including MIT, Harvard Medical School and the University of Cambridge, has unveiled a faster, more efficient approach to cancer diagnosis and biomarker profiling with better accuracy that accelerates and democratizes precision medicine for optimized patient care and clinical trials. The company, which has raised $6.4 million in funding to date, applies its cloud-base